This is a clinical trial for men and women with relapsed or refractory multiple myeloma. The main purpose of this study is to test the safety of a new experimental oral drug called CC-122, a Pleiotropic Pathway Modulator (PPM). This class of medication aims to stop the growth of cancerous cells by binding to a protein complex linked to cell division.
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.